Information Provided By:
Fly News Breaks for September 16, 2019
AIMT, DBVT
Sep 16, 2019 | 05:22 EDT
Bryan Granier analyst Hugo Solvet says the FDA during Friday's panel hearing for Aimmune Therapeutics (AIMT) laid out a path to approval for DBV Technologies (DBVT). A presentation during the committee meeting pointed to DBV's epicutaneous immunotherapy as a potential treatment, with Aimmune's oral immunotherapy used for maintenance, Solvet tells investors in a research note. He also believes a black box warning and treatment logistics will hold back the commercial potential of Aimmune's Palforzia. The analyst keeps a Buy rating on DBV Technologies with a price target of 46 euros. The stock in premarket trading is up 13c to $10.38.
News For DBVT;AIMT From the Last 2 Days
There are no results for your query DBVT;AIMT